Argenx Se (ARGX) Revenue Growth (3y) (2019 - 2026)
Argenx Se (ARGX) Revenue Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 50.07% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 7.94% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 4.47% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 79.44% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 37.29 Bn | 34.28 Bn | 959.66 Mn | 54.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 79.44% |
| Mar 31, 2026 | 81.24% |
| Dec 31, 2025 | 95.00% |
| Sep 30, 2025 | 104.73% |
| Jun 30, 2025 | 133.16% |
| Mar 31, 2025 | 234.21% |
| Dec 31, 2024 | 204.81% |
| Sep 30, 2024 | -91.26% |
| Jun 30, 2024 | 14.87% |
| Mar 31, 2024 | 37.89% |
| Dec 31, 2023 | 137.77% |
| Sep 30, 2023 | 235.27% |
| Jun 30, 2023 | 319.01% |
| Mar 31, 2023 | 117.67% |
| Dec 31, 2022 | 71.29% |
| Sep 30, 2022 | 278.88% |
| Jun 30, 2022 | 53.98% |
| Mar 31, 2022 | -20.10% |
| Dec 31, 2021 | 34.94% |
| Sep 30, 2021 | 4,672.46% |